Related Experiment Video
Updated: Jun 23, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome
Augusto Pasini1, Elisa D'Agati, Livia Casarelli
1Department of Neuroscience, University of Rome Tor Vergata, Roma, Italy. pasini@uniroma2.it
Abstract:
We describe a 18-year-old female with 22q13.3 deletion syndrome characterized by an alteration of SHANK3/PROSAP2 and severe mental retardation, intense psychomotor agitation and aggressive behaviour. When the patient was given risperidone, different therapeutic results were observed: at a 6 mg dose, risperidone had no therapeutic effect and the patient's behavioural problems increased; at a low dose (1mg), risperidone treatment resulted in rapid improvement of mood and behaviour. Recent findings suggest that risperidone exerts dose-dependent effects on Glu receptors in developing rats. An altered preset of the glutamate receptors, due to the presence of a haploinsufficiency of SHANK3/PROSAP2, could explain the different results of risperidone therapy observed in our patient with 22q13.3 deletion syndrome.
Related Concept Videos
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Dosing: Infants and Children
Antipsychotic Drugs: Typical and Atypical Agents
Drug Toxicity: Dose-Dependent Reactions
Factors Affecting Drug Response: Overview
